154848-44-9

Basic information

• Product Name: 4'-HYDROXYBIPHENYL-3-CARBONITRILE
• Synonyms: 3-(4-HYDROXYPHENYL)BENZONITRILE;SALOR-INT L300713-1EA;4μ-Hydroxy-[1,1μ-biphenyl]-3-carbonitrile, 4μ-Hydroxybiphenyl-3-carbonitrile;4-(3-Cyanophenyl)phenol;4'-hydroxy-3-biphenylcarbonitrile;4'-HYDROXYBIPHENYL-3-CARBONITRILE;4'-HYDROXY[1,1'-BIPHENYL]-3-CARBONITRILE;AKOS BAR-0928
• CAS NO: 154848-44-9
• Molecular Formula: C₁₃H₉NO
• Molecular Weight: 195.22
• Mol File: 154848-44-9.mol

Chemical Properties

• Melting Point: 164-168 °C(lit.)
• Boiling Point: 373.4°Cat760mmHg
• Flash Point: 179.7°C
• Appearance: /
• Density: 1.24g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.52±0.26(Predicted)
• CAS DataBase Reference: 4'-HYDROXYBIPHENYL-3-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 4'-HYDROXYBIPHENYL-3-CARBONITRILE(154848-44-9)
• EPA Substance Registry System: 4'-HYDROXYBIPHENYL-3-CARBONITRILE(154848-44-9)

Safety Data

• Hazard Codes: Xn,N
• Statements: 20/21/22-41-51/53
• Safety Statements: 26-36/37/39-61
• RIDADR: UN 3077 9/PG 3
• WGK Germany: 2
• Hazardous Substances Data: 154848-44-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4'-HYDROXYBIPHENYL-3-CARBONITRILE is used as a key intermediate in organic synthesis for the production of various organic compounds. Its unique structure allows for further chemical reactions and modifications, facilitating the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4'-HYDROXYBIPHENYL-3-CARBONITRILE is utilized as a starting material or intermediate in the development of new pharmaceuticals. Its potential applications in the production of various pharmaceuticals make it an essential component in drug discovery and design.
Used in Agrochemical Production:
4'-HYDROXYBIPHENYL-3-CARBONITRILE also finds applications in the agrochemical sector, where it is used in the synthesis of various agrochemicals. Its properties and reactivity contribute to the development of effective and targeted agrochemical products.

Upstream product

• 110-71-4 1,2-dimethoxyethane 
• 69113-59-3 3-iodobenzonitrile 
• 5720-07-0 4-methoxyphenylboronic acid 
• 540-38-5 p-Iodophenol 
• 150255-96-2 (3‐cyanophenyl)boronic acid 
• 154197-00-9 3-cyano-4'-methoxybiphenyl 
• 106-41-2 4-bromo-phenol 

Downstream Products

• 1593090-63-1 5-(4'-(3-phenylpropoxy)-[1,1'-biphenyl]-3-yl)-1H-tetrazole 
• 1593090-62-0 C₂₁H₁₈N₄O 
• 1593090-69-7 4'-phenethoxy-[1,1'-biphenyl]-3-carbonitrile 
• 935759-93-6 N-{[4'-({5-[2-(ethyloxy)ethyl]-2,4,6-trioxohexahydropyrimidin-5-yl}oxy)biphenyl-3-yl]methyl}-4-oxo-3,4-dihydroquinazoline-2-carboxamide 
• 935760-81-9 N-[(4'-hydroxybiphenyl-3-yl)methyl]-4-oxo-3,4-dihydroquinazoline-2-carboxamide 
• 808769-20-2 3'-(aminomethyl)biphenyl-4-ol 
• 921598-25-6 2-(3-{2-[((2R)-2-{4-benzyloxy-3-[(methylsulfonyl)amino]phenyl}-2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)amino]-2-methylpropyl}phenyl)-N-[(4'-hydroxybiphenyl-3-yl)methyl]-acetamide 
• 921598-21-2 2-[3-(2-amino-2-methylpropyl)phenyl]-N-[(4'-hydroxybiphenyl-3-yl)methyl]acetamide 
• 1354787-50-0 4'-Hydroxy-3'-(pyridazin-4-yl)biphenyl-3-carbonitrile 
• 1354787-49-7 5-Chloro-4-(3'-cyano-3-(pyridazin-4-yl)biphenyl-4-yloxy)-N-(2,4-dimethoxybenzyl)-2-fluoro-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide 
• 1354786-51-8 5-chloro-4-[(3'-cyano-3-pyridazin-4-ylbiphenyl-4-yl)oxy]-2-fluoro-N-1,3,4-thiadiazol-2-ylbenzenesulfonamide 
• 935758-94-4 4'-({5-[2-(ethyloxy)ethyl]-2,4,6-trioxohexahydropyrimidin-5-yl}oxy)biphenyl-3-carbonitrile 
• 192376-61-7 (2R)-4-(3-pyridyl)-2-benzoyloxy-1-(3'-cyanobiphenyl-4-yloxy)butane 

Relevant articles and documents

BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA

The invention relates to bimesogenic compounds of formula Iwherein R 11 , R 12 , MG 1 , MG 2 , X 11 , X 12 and Sp 1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and in particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.

3-Hydroxypyrimidine-2,4-diones as Selective Active Site Inhibitors of HIV Reverse Transcriptase-Associated RNase H: Design, Synthesis, and Biochemical Evaluations

Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RNase H) remains an unvalidated antiviral target. A major challenge of specifically targeting HIV RNase H arises from the general lack of selectivity over RT polymerase (pol) and integrase (IN) strand transfer (ST) inhibitions. We report herein the synthesis and biochemical evaluations of three novel 3-hydroxypyrimidine-2,4-dione (HPD) subtypes carefully designed to achieve selective RNase H inhibition. Biochemical studies showed the two subtypes with an N-1 methyl group (9 and 10) inhibited RNase H in low micromolar range without siginificantly inhibiting RT polymerase, whereas the N-1 unsubstituted subtype 11 inhibited RNase H in submicromolar range and RT polymerase in low micromolar range. Subtype 11 also exhibited substantially reduced inhibition in the HIV-1 INST assay and no significant cytotoxicity in the cell viability assay, suggesting that it may be amenable to further structure-activity relationship (SAR) for identifying RNase H inhibitors with antiviral activity.

Inhibitors of nedd8-activating enzyme

The invention relates to an administration unit comprising crystalline form I of {(1 S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (I-216) hydrochloride salt and to a packaging comprising the administration unit according to the invention.

INTERMEDIATE AND PROCESS FOR THE PREPARATION OF A SULFONAMIDE DERIVATIVE

The invention relates to a crystalline form of 2-chloro-N-{2-[3-(2-{[(4'-hydroxybiphenyl-3- yl)methyl]amino}-2-oxoethyl)phenyl]-1,1-dimethylethyl}acetamide, a process for preparing the same and its use in the preparation of the ?2 agonist N-[(4'-hydroxybiphenyl-3- yl)methyl]-2-(3-{2-[((2R)-2-hydroxy-2-{4-hydroxy-3- [(methylsulfonyl)amino]phenyl}ethyl)amino]-2-methylpropyl} phenyl)acetamide which is useful in the treatment of respiratory diseases.

Chemical Compounds

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new sulfonamide Nav1.7 inhibitors of formula (I): or pharmaceutically acceptable salts thereof, wherein Z1, Ra, Rb, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

ORGANOMETALLIC COMPLEXES

Organometallic complexes are provided, methods for making the same, and their use in devices and sub-assemblies.

ERbeta ligands. Part 1: the discovery of ERbeta selective ligands which embrace the 4-hydroxy-biphenyl template.

The synthesis and structure-activity relationships of a series of simple biphenyls is described. Optimization of the 4-hydroxy-biphenyl template led to compounds with ERbeta selectivity on the order of 20-70-fold.

N-HYDROXYFORMAMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES

Compounds having formula (I) are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.

REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES

Compounds having the formula are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.

Reverse hydroxamate inhibitors of matrix metalloproteinases

Compounds having the formula are matrix metalloproteinase inhibitors. Also disclosed are matrix metalloproteinase-inhibiting compositions and methods of inhibiting matrix metalloproteinase in a mammal.